Facebook
Twitter
LinkedIn
Forward2024 Seattle Lung Cancer Conference
This CME-accredited activity, the 2024 Seattle Lung Cancer Conference, brings together leaders in the field of thoracic oncology to provide an extensive overview of both current and emerging strategies for managing lung cancer (NSCLC and SCLC). The primary aim of this conference is to enhance the knowledge and competence of participants, enabling them to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for lung cancer patients. The program includes detailed discussions and analyses of the latest scientific discoveries and advancements in molecular testing and targeted therapies for thoracic oncology. The expert faculty will focus on the clinical application of diagnostics, biomarkers, and various therapeutic agents, discussing how these tests and treatments can be effectively used to improve patient care.
Target Audience
- Medical Oncologists
- Surgeons
- Radiation Oncologists
- Pathologists
- Oncology Fellows
- Oncology Nurses
- Nurse Practitioners
- Physician Assistants
- Pharmacists
ORGANIZING COMMITTEE
Conference Director:
Binay Shah, MD, MHA - Binaytara Foundation
Conference Chair:
Siddhartha H Devarakonda, MD - Swedish Cancer Institute
Associate Chairs:
Lei Deng, MD - Fred Hutchinson Cancer Center
Jessica Hellyer, MD - Providence
Learning Objectives
At the conclusion of the activity, participants will be able to:
- Review the various actionable molecular abnormalities in lung cancer and learn about the appropriate testing and treatment strategies for these alterations.
- Summarize the efficacy and potential toxicities of immune checkpoint inhibitors, targeted therapies, and other chemotherapy agents in the management of lung cancer.
- Identify the role of perioperative systemic therapy options in curative-intent treatment of non-small cell lung cancer (NSCLC), including chemotherapy, immune checkpoint inhibitors, and targeted therapies.
- Apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with lung cancer.
SPONSORSHIP ACKNOWLEDGEMENT
We want to thank our Platinum Sponsor AstraZeneca
HOTEL INFORMATION
A limited number of guestrooms are reserved at the Hilton Motif for the participants of this meeting at a discounted rate of $189 per night. The room rate does not include any additional fees or applicable taxes.
CUTOFF - Tuesday October 1, 2024
Parking
Hotel offers self-parking for $73.04 per day on-site.
GLOBAL ONCOLOGY PROJECT
To learn more about our ongoing project building a 200-bed cancer hospital in Nepal:
November 2nd, 2024
All times are listed in Pacific Daylight Time (PDT)
07:00 AM – 07:30 AM Registration, Breakfast, & Exhibits
07:30 AM – 07:50 AM Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA
07:50 AM – 08:00 AM Opening Remarks - Sid Devarakonda, MD
08:00 AM – 09:00 AM Session 1 - Pathology, Genetics and Biomarkers
Session Chair: Jessica Hellyer, MD
08:00 AM – 08:15 AM Pathological Classification of Thoracic Tumors - Christin Lepus, MD, PhD
08:15 AM – 08:30 AM Germline Testing and Lung Cancer - Marianne Dubard-Gault, MD, MS
08:30 AM – 08:45 AM Genomics and Biomarkers: Thoracic Oncology in 2024 - Sid Devarakonda, MD
08:45 AM – 09:00 AM Panel Discussion
09:00 AM – 09:45 AM Break & Exhibits
Product Theater Sponsored by AstraZeneca in breakout room.
Title: A Treatment Option for Certain Patients With Unresectable Stage III EGFRm NSCLC Following CRT
Speaker: Arya Amini, MD; Chief of Thoracic Radiotherapy, City of Hope Comprehensive Cancer Center
*This is a non-CME accredited activity*
09:45 AM – 11:05 AM Session 2 - Controversies in Thoracic Oncology
Session Chair: Lei Deng, MD
Debate: Locally Advanced NSCLC: Is Surgery the New Standard of Care?
09:45 AM – 10:00 AM Yes - Eric Vallières, MD, FRCSC
10:00 AM – 10:15 AM No - Annemarie Shepherd, MD
10:15 AM – 10:25 AM Panel Discussion
Debate: Is There a Role for Surgery in Managing Mesothelioma?
10:25 AM – 10:40 AM Yes - Adam Bograd, MD
10:40 AM – 10:55 AM No - Jeffrey Ward, MD, PhD
10:55 AM – 11:05 AM Panel Discussion
11:05 AM – 12:20 PM Session 3 - Frontline Therapy in Lung Cancer
Session Chair: Sid Devarakonda, MD
Debate: Frontline Therapy in Lung Cancer - EGFR
11:05 AM – 11:20 AM More is Better - Matthew Gubens, MD, MS, FASCO
11:20 AM – 11:35 AM More is NOT Better - Christina Baik, MD, MPH
Debate: Frontline Therapy in Lung Cancer - Immunotherapy
11:35 AM – 11:50 AM More is Better: Dual Immune Checkpoint Inhibition and Quad Regimens - Jessica Hellyer, MD
11:50 AM – 12:05 PM More is NOT Better: Triplet and Single Agent IO is the Standard - Joseph Rosales, MD
12:05 PM – 12:20 PM Panel Discussion
12:20 PM – 01:20 PM Lunch & Exhibits
01:20 PM – 02:20 PM Session 4 - Current Standards and Emerging Therapies
Session Chair: Jessica Hellyer, MD
01:20 PM – 01:35 PM NSCLC: Immunotherapy - Chetan Vakkalagadda, MD
01:35 PM – 01:50 PM NSCLC: Targeted Therapies - Mohana Roy, MD
01:50 PM – 02:05 PM Small Cell - Rafael Santana-Davila, MD
02:05 PM – 02:20 PM Panel Discussion
02:20 PM – 03:50 PM Session 5 - Rapid Reviews
Session Chair: Sid Devarakonda, MD
02:20 PM – 02:35 PM How I Approach Peri-Operative Therapy - Lei Deng, MD
02:35 PM – 02:50 PM ADCs: Hope or Hype? - Smitha Menon, MD
02:50 PM – 03:05 PM ALK, HER2, ROS, RET, and MET in 2024 - Keith Eaton, MD, PhD
03:05 PM – 03:20 PM Post -Targeted Therapy Landscape in NSCLC - Diane Tseng, MD, PhD
03:20 PM – 03:35 PM How I Approach Oligometastatic Disease - Puneeth Iyengar, MD, PhD
03:35 PM – 03:50 PM Panel Discussion
03:50 PM – 04:10 PM Break & Exhibits
04:10 PM – 04:40 PM Session 6 - The Real World in Thoracic Oncology
Session Chair: Carly Irwin, RN
04:10 PM – 04:20 PM Thoracic Oncology Nursing Challenges - Carly Irwin, RN
04:20 PM – 04:40 PM Panel Discussion - Katie Johnson, MSN, RN, OCN; Lisa Masiello, PhD, CCRP, RAC; Daylyn Harris, RN, OCN; Molly Tokaz, MD
04:40 PM – 05:10 PM Session 7 - Challenging Cases
Session Chair: Nicholas Giustini, MD
04:40 PM – 05:10 PM Panel Discussion - Puneeth Iyengar, MD, PhD; Vyshak Venur, MD; Madhan Kumar Kuppusamy MD, FRCS (C-Th); Zhaohui Lao Arter, MD
05:10 PM Adjourn
HOTEL INFORMATION
A limited number of guestrooms are reserved at the Hilton Motif for the participants of this meeting at a discounted rate of $189 per night. The room rate does not include any additional fees or applicable taxes.
CUTOFF - Tuesday October 1, 2024
Parking
Hotel offers self-parking for $73.04 per day on-site.
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Siddhartha Devarakonda, MBBS, MD
Nicholas Giustini, MD
vyshak Alva Venur
Christina Baik, MD MPH
Adam Bograd, M.D.; Thoracic Surgeon
Marianne Dubard-Gault, MD, MS
Keith Eaton, MD, PhD
Matthew Gubens
Puneeth Iyengar, MD, PhD
Katie Johnson, MSN, RN, OCN
Christin Lepus, MD, PhD
Lisa Masiello
Smitha Menon
Joseph Rosales, MD
Mohana Roy, MD
Rafael Santana-Davila, MD
Annemarie Shepherd, MD
Molly Tokaz
Diane Tseng, MD PhD
Chetan Vakkalagadda
Eric Vallieres, MD, FRCS(C)
Jeffrey Ward, MD Ph.D
Zhaohui Arter, MD
Nicholas Giustini, MD
Daylyn Harris
Lei Deng, MD
Jessica Hellyer
Acknowledgement of Commercial Support
This activity is supported with Independent Medical Education Grants from:
- Exact Sciences
- MSD
- Varian Medical Systems
Available Credit
- 7.00 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 7.00 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 7.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 7.00 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 7.00 Contact Hours.
Platinum Sponsor:
Astrazeneca
Featured Exhibitor:
Daiichi Sankyo
| Company | Exhibit type | Requester Name | 2nd Rep Name |
| Incyte | General Exhibit | Jennifer Kinman | |
| Foundation Medicine | General Exhibit | Julie Benefiel, PharmD | Katie Baker, PhD |
| BMS | General Exhibit | Ashley Siegel | |
| J & J PT | Lunch PT | Gina Hurley | Ashley Korn |
| Pfizer | General Exhibit | Michele Almeda | |
| Takeda | General Exhibit | Sean Nealis | |
| Eli Lilly | General Exhibit | Nancy Junes | Kevin McGowan |
| Boehringer-Ingelheim | General Exhibit | David Waldron | |
| Regeneron | General Exhibit | Manny Alamario | Erin Olson |
| Tempus | General Exhibit | Julia Appelbaum | Jamie Sison |
| Amgen | General Exhibit | Brandon Cogo | Sarah Ahadome |
| Guardant Health | General Exhibit | Lara Esteb | |
| Jazz Pharma | General Exhibit | Kevin Watson | |
| Astrazeneca PT | AM Break PT | ||
| Nuvation Bio | Charging Station | Charlie Jones | Matt Young |
| J & J exhibit table | General Exhibit | Morgan Anderson | Audrey Baier |
| Merck | General Exhibit | Michael Murphy | |
| Billion-To-One | General Exhibit | Kim Schliesman | Ali Aboosaiedi |
| Natera | General Exhibit |
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.